載入中
Eledon Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to creating innovative treatments for individuals battling autoimmune disorders, amyotrophic lateral sclerosis (ALS), and those undergoing organ or cell transplantation. Their flagship therapeutic candidate, AT-1501, is a humanized monoclonal antibody engineered to specifically target CD40 Ligand, a crucial protein found on the surface of immune system T cells. This compound is currently undergoing Phase 2a clinical studies for ALS treatment and Phase 2 trials for islet cell transplantation, aiming to address type 1 diabetes. Previously known as Novus Therapeutics, Inc., the company adopted its current name, Eledon Pharmaceuticals, Inc., in January 2021. Its corporate headquarters are located in Irvine, California.
前收盤價
US$2.48
+US$0.06 · +2.48%
盤中時間採用ET。市場資料可能有所延遲。
Eledon Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to creating innovative treatments for individuals battling autoimmune disorders, amyotrophic lateral sclerosis (ALS), and those undergoing organ or cell transplantation. Their flagship therapeutic candidate, AT-1501, is a humanized monoclonal antibody engineered to specifically target CD40 Ligand, a crucial protein found on the surface of immune system T cells. This compound is currently undergoing Phase 2a clinical studies for ALS treatment and Phase 2 trials for islet cell transplantation, aiming to address type 1 diabetes. Previously known as Novus Therapeutics, Inc., the company adopted its current name, Eledon Pharmaceuticals, Inc., in January 2021. Its corporate headquarters are located in Irvine, California.
日內區間
目前US$2.48
52週區間
目前US$2.48
盤中時間採用ET。市場資料可能有所延遲。
Eledon Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to creating innovative treatments for individuals battling autoimmune disorders, amyotrophic lateral sclerosis (ALS), and those undergoing organ or cell transplantation. Their flagship therapeutic candidate, AT-1501, is a humanized monoclonal antibody engineered to specifically target CD40 Ligand, a crucial protein found on the surface of immune system T cells. This compound is currently undergoing Phase 2a clinical studies for ALS treatment and Phase 2 trials for islet cell transplantation, aiming to address type 1 diabetes. Previously known as Novus Therapeutics, Inc., the company adopted its current name, Eledon Pharmaceuticals, Inc., in January 2021. Its corporate headquarters are located in Irvine, California.
日內區間
目前US$2.48
52週區間
目前US$2.48
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 研究與開發 | 6626.7萬 USD | 5196.4萬 USD | 3031.2萬 USD | 2708萬 USD | 2373.5萬 USD |
| 銷售、一般及管理費用 | 1698.4萬 USD | 1861.3萬 USD | 1268.8萬 USD | 1270萬 USD | 1313.2萬 USD |
| 營業費用 | 8325.1萬 USD | 7057.7萬 USD | 4300萬 USD | 8842.8萬 USD | 3686.7萬 USD |
| 折舊和攤銷 | 31.3萬 USD | 35.9萬 USD | 37.4萬 USD | 37.3萬 USD | 19.5萬 USD |
| 營業利益 | −8325.1萬 USD | −7057.7萬 USD | −4300萬 USD | −8842.8萬 USD | −3686.7萬 USD |
| 淨利 | −4561.7萬 USD | −3618.4萬 USD | −1.17億 USD | −8796.6萬 USD | −3450.6萬 USD |
公司資料更新於 2026年10月11日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI739.98萬0.00%2.3兆 USD0.03%US$381.94+0.63%
iShares Russell 2000 ETFIWM504.04萬0.01%787.4億 USD0.19%US$278.94+0.49%
Vanguard Extended Market ETFVXF254.68萬0.00%954億 USD0.05%US$235+0.80%
iShares Russell 2000 Growth ETFIWO174.39萬0.01%139.17億 USD0.24%US$356.78+0.94%
Vanguard Russell 2000 ETFVTWO131.58萬0.01%180億 USD0.06%US$112.66+0.50%
Dimensional - US Small Cap ETFDFAS60.92萬0.00%338.69億 USD0.31%US$78.35+0.32%
iShares Micro-Cap ETFIWC58.42萬0.04%13.17億 USD0.60%US$183+0.11%
Goldman Sachs ActiveBeta U.S. Small Cap Equity ETFGSSC27.08萬0.03%10.45億 USD0.20%US$86.29+0.43%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOVanguard Russell 2000 ETFVTWODimensional - US Small Cap ETFDFASiShares Micro-Cap ETFIWCGoldman Sachs ActiveBeta U.S. Small Cap Equity ETFGSSCAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
